Gene Signal is a research and development based biotechnology company focused on discovering genes involved in the regulation of angiogenesis.
Gene Signal's ophthalmic research program is pioneering targeted upstream blockade of pathological angiogenesis through the inhibition of Insulin Receptor Substrate 1 (IRS-1)
“Topical Aganirsen produces a highly significant regression of corneal neovascularization”
Cursiefen C., Ophthalmology.
2009 SEP;116(9):1630-7
“Topical application of Aganirsen offers a safe and effective therapy for both choroidal and retinal neovascularization without preventing its normal vascularization”
Cloutier F. Invest Ophthalmol,
Vis Sci. 2012 Mar 9 ;
53(3) :1195-203